Australian medical device maker Baymatob has closed an equity placement of A$4.215 million ($3 million), proceeds from which will be used to complete its in-human clinical trials for its AI-enabled labour monitoring device.
The placement includes cornerstone funding from the Future of Healthcare Fund of insurance firm Australian Unity.
WHAT IT'S FOR
Baymatob's flagship device Oli uses sensors and...
![[Left] Tara Croft, Baymatob CEO; [Center] Dr Sarah McDonald, CVO and founder; [Right] Victor Windeyer, fund manager at Australian Unity](https://www.mobihealthnews.com/sites/default/files/styles/230x130/public/sarah%20tara%20vic.jpg?itok=t_6820zc)
